Dermaliq Therapeutics
Manufacturing · Delaware, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1201 N Market St Ste 111, Wilmington, De...Website
www.dermaliq.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Dermaliq Therapeutics
dermaliq Therapeutics, Inc., is a newly formed Delaware-based specialty pharma company that emerged from Novaliq GmbH in Germany by spin off. It is leveraging its ground-breaking hyliQ® technology platform to develop and commercialize the next generation of medicines to benefit patients with significant unmet medical needs in dermatology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dermaliq Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Dermaliq Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Dermaliq Therapeutics has new funding data
Check if Dermaliq Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Dermaliq Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Dermaliq Therapeutics
Click to see if Dermaliq Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Dermaliq Therapeutics recently announced quarterly report
Product Launch: Get notified when Dermaliq Therapeutics launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Dermaliq Therapeutics
Find more new buyers
Compare Similar Companies to Dermaliq Therapeutics
Compare insights from companies similar to Dermaliq Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Dermaliq Therapeutics
<$5M
1-10
Private
$15M
2021
N/A
Company Profile Activity
Activity Insights
Dermaliq Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dermaliq Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dermaliq Therapeutics.
Dermaliq Therapeutics financials insights
Gather financial insights about Dermaliq Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$15M
Dermaliq Therapeutics Tech Stack
A closer look at the technologies used by Dermaliq Therapeutics
See more technologies
Dermaliq Therapeutics News & Media
Dermaliq Therapeutics announces first patient dosed in Phase 1b/2 trial evaluating DLQ02 for treatment of plaque psoriasis
WILMINGTON, Del.--(BUSINESS WIRE)--Dermaliq Therapeutics, Inc. (Dermaliq), a private, clinical stage pharmaceutical company with a focus on dermatology, today announced first patient dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaque psoriasis. “DLQ02 evaluates for the first time hyliQTM, a novel platform technology in dermatology toDermaliq appoints Gordon Dow, PharmD, Michael Kuligowski, MD, PhD, R. Todd Plott, MD and Xavier Yon to its Dermatology Scientific and Medical Advisory Board
WILMINGTON, Del.--(BUSINESS WIRE)--Dermaliq Therapeutics, Inc. (Dermaliq), a private biopharmaceutical company with therapeutic focus on dermatology, today announces the formation of a Scientific and Medical Advisory Board composed of internationally recognized experts in dermatology, Gordon Dow (San Francisco, US,), Xavier Yon (Paris, France), Michael Kuligowski, MD, PhD (Chads Ford, US) and R. Todd Plott, MD (Dallas/Fort Worth, US). The Advisory Board is composed of key clinical investigators
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Dermaliq Therapeutics
Sign Up For FreeTo access detailed company insights
dermaliq Therapeutics, Inc., is a newly formed Delaware-based specialty pharma company that emerged from Novaliq GmbH in Germany by spin off. It is leveraging its ground-breaking hyliQ® technology platform to develop and commercialize the next generation of medicines to benefit patients with significant unmet medical needs in dermatology.... Read More
